Kazia Therapeutics (KZIA) Accumulated Expenses (2015 - 2025)

Kazia Therapeutics' Accumulated Expenses history runs 11 years deep, the most recent figure standing at $249768.9 for Q2 2025.

• Quarterly Accumulated Expenses rose 3.84% year-over-year to $249768.9 in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $249768.9 (up 3.84% YoY) and the FY2025 annual result came in at $249768.9, up 3.84% from the prior year.
• Accumulated Expenses was $249768.9 for Q2 2025 at Kazia Therapeutics, up from $240543.9 in the prior quarter.
• Across five years, Accumulated Expenses topped out at $461168.7 in Q2 2023 and bottomed at $118900.5 in Q2 2022.
• A 5-year average of $249345.0 and a median of $240543.9 in 2024 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2023 — Accumulated Expenses jumped 287.86% — and 2024, when it tumbled 47.84%.
• Kazia Therapeutics' Accumulated Expenses stood at $176342.6 in 2021, then plunged by 32.57% to $118900.5 in 2022, then soared by 287.86% to $461168.7 in 2023, then tumbled by 47.84% to $240543.9 in 2024, then grew by 3.84% to $249768.9 in 2025.
• Business Quant data shows KZIA's Accumulated Expenses at $249768.9 in Q2 2025, $240543.9 in Q2 2024, and $461168.7 in Q2 2023.